A Well-Balanced Pipeline

Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.

 

Promising Developments in our Pipeline

 

Compound* Clinical phase Indication Therapeutic principle Mode of action
Idarucizumab Submitted, Phase III Study ongoing Reversal of anticoagulant effect of dabigatran etexilate Specific binding of dabigatran etexilate with humanized antibody fragment (Fab) Specific reversal of dabigatran etexilate
Linagliptin** Phase IV

Diabetes mellitus type II in patients with high cardiovascular risk

 Dipeptidyl peptidase (DPP) 4 inhibitor Inhibition of dipeptidyl peptidase (DPP) 4
Afatinib Phase III Lung squamous cell carcinoma Signal transduction inhibition Novel irreversible ErbB Family blocker
Afatinib Phase III Head and neck squamous cell carcinoma Signal transduction inhibition Novel irreversible ErbB Family blocker
BI 695500 Phase III Rheumatoid arthritis Depletion of CD20-positive B-cell-subpopulations Monoclonal anti-CD20 antibody
BI 695501 Phase III Rheumatoid arthritis Inhibition of TNFα Monoclonal anti-tumor necrosis factor-alpha (TNFα) antibody
BI 695502 Phase III Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) Angiogenesis inhibition Angiogenesis inhibitor blocks vascular endothelial growth factor (VEGF)
Dabigatran etexilate Phase III Secondary stroke prevention in patients who have already suffered an embolic stroke of undetermined source Oral anticoagulation Direct reversible thrombin inhibitor (DTI)
Dabigatran etexilate Phase IIIb Stroke prevention in patients with non-valvular atrial fibrillation - uninterrupted anticoagulant treatment in patients with AF who undergo ablation Oral anticoagulation Direct reversible thrombin inhibitor (DTI)
Dabigatran etexilate Phase IIIb Stroke prevention in patients with non-valvular atrial fibrillation – antithrombotic therapy after PCI with stenting Oral anticoagulation Direct reversible thrombin inhibitor (DTI)
Empagliflozin** Phase III

Diabetes mellitus type II in patients with high cardiovascular risk

 SGLT2-inhibition Inhibition of sodium glucose cotransporter-2
Linagliptin** Phase III Diabetes mellitus type II in patients with renal disease

Dipeptidyl peptidase (DPP) 4 inhibitor

 Inhibition of dipeptidyl peptidase (DPP) 4
Nintedanib Phase III Colorectal cancer Angiogenesis inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Volasertib Phase III Acute Myeloid Leukemia (AML) Cell-cycle kinase inhibition PLK-1 antagonist
BI 409306 Phase II Schizophrenia Enhanced glutamatergic signaling Phosphodiesterase (PDE) 9 inhibitor
BI 409306 Phase II Prodromal Alzheimer’s Dementia Enhanced glutamatergic signaling Phosphodiesterase (PDE) 9 inhibitor
BI 409306 Phase II Alzheimer’s Dementia Enhanced glutamatergic signaling Phosphodiesterase (PDE) 9 inhibitor
BI 655066 Phase III in preparation Psoriasis Inhibition of IL-23 Monoclonal anti-IL-23 antibody
BI 655066 Phase III in preparation Psoriatric Arthritis Inhibition of IL-23 Monoclonal anti-IL-23 antibody
BI 655066 Phase II Crohn’s Disease Inhibition of IL-23 Monoclonal anti-IL-23 antibody
BI 655066 Phase II Ankylosing Spondylitis Inhibition of IL-23 Monoclonal anti-IL-23 antibody
BI 655064 Phase II in preparation Lupus Nephritis Inhibition of CD-40 Monoclonal anti-CD-40 antibody

* These are investigational agents; their safety and efficacy have not yet been established.
** In collaboration with Eli Lilly and Company

Status: April 2015

Successful Products from our own Research & Development

Product name First launch Active ingredient Indication
Praxbind® 2015 Idarucizumab Reversal of the anticoagulant effects of dabigatran
Spiolto® Respimat® 2015 Tiotropium/Olodaterol Chronic obstructive pulmonary Disease (COPD)
Synjardy® 2015 Empagliflozin/ Metformin hydrochloride Diabetes mellitus type II
Glyxambi®** 2015 Empagliflozin/Linagliptin Diabetes mellitus type II
Vargatef® 2015 Nintedanib Non-small cell lung cancer (NSCLC)
Ofev® 2014 Nintedanib Idiopathic pulmonary fibrosis (IPF)
Spiriva® Respimat® 2014 Tiotropiumbromide Asthma
Striverdi® Respimat® 2014 Olodaterol Chronic obstructive pulmonary Disease (COPD)
Jardiance®** 2014 Empaglifozin Diabetes mellitus type II
Pradaxa® 2014 Dabigatran etexilate Treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
Giotrif® /  Gilotrif™ 2013 Afatinib Non-small cell lung cancer (NSCLC)
Jentadueto®** 2012 Linagliptin+Metformin Diabetes mellitus type II
Trajenta®** 2011 Linagliptin Diabetes mellitus type II
Pradaxa®

2010

Dabigatran etexilate

Stroke prevention in atrial fibrillation
Twynsta® 2010 Telmisartan+Amlodipine Essential hypertension
Pradaxa® 2008 Dabigatran etexilate Prevention of venous thromboembolic events (VTE) in adults

Spiriva® Respimat®

 

Spiriva® Handihaler®

2007

 

2002

Tiotropiumbromide

Tiotropiumbromide

COPD

COPD
Micardis® 1998 Telmisartan Essential hypertension
Sifrol® / Mirapex® /

Mirapexin®

2006

 

1997

Pramipexole

Restless legs syndrome (RLS)

 

Parkinson's disease (PD)
Viramune® 1996 Nevirapine HIV/AIDS

** In collaboration with Eli Lilly and Company

Status: April 2015